Skip to main content
. 2012 Jun;32(Suppl 2):S32–S86. doi: 10.3747/pdi.2011.00091

Figure 1.

Figure 1

— Empiric therapy.

a If the center’s rate of methicillin-resistant Staphylococcus aureus (MRSA) exceeds 10%, or if the patient has history of MRSA infection or colonization, glycopeptide (vancomycin or teicoplanin) should be added to cefepime or should replace the first-generation cephalosporin for gram-positive coverage. Glycopeptide use can also be considered if the patient has a history of severe allergy to penicillins and cephalosporins.